| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.1 | 0.09 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.089 | 0.09 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.09 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.09 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.049 | 0.09 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.12 | 0.09 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |